Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Update in asthma management

천식치료의 최신지견

  • Lee, Hae Ran (Department of Pediatrics, Medical College, Hallym University)
  • 이혜란 (한림대학교 의과대학 소아과학교실)
  • Received : 2006.05.12
  • Accepted : 2006.05.15
  • Published : 2006.06.15
Download PDF
⟨ Previous Next ⟩

Abstract

Asthma is a chronic inflammation of the airway associated with increased bronchial hyperresponsiveness that leads to recurrent episodes of cough, wheezing, breathless, chest tightness. According the recent studies, repeated airway inflammation leads to structural changes so called 'airway remodeling' and associated with decreased pulmonary function. Airway remodeling begins form the early stage of asthma and the early diagnosis and management is very important to prevent airway remodeling. Medication for asthma can be classified into acute symptom reliever and chronic controller. Short acting beta2 agonist is a well-known reliever that reduced asthma symptoms within minutes. Controllers should be taken daily as a long-term basis to control airway inflammation. Inhaled corticosteroid(ICS) is the most effective controller in current use. However, in some patients ICS monotherapy is not sufficient to control asthma. In those cases, other medications such as long acting beta2 agonist, leukotriene modifier or sustained-release theophylline should be added to ICS, which called Add-on-Therapy. Combination inhaler devices are easy to use. Oral leukotriene modifier has a good compliance especially in children. Finally, as asthma is a chronic disease, the development of on-going partnership among health care professionals, the patients, and the patients' family is necessary for the effective management of asthma.

Keywords

References

  1. National Asthma Education and Prevention Program. Expert Panel Report : guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol 2002;110:S141-219 https://doi.org/10.1016/S0091-6749(02)80002-1
  2. The Korean Academy of Pediatric Allergy and Respiratory Disease. 2003 Guidelines for management of childhood asthma. Seoul : Kunja Publications, 2003:3-92
  3. The Korean Academy of Asthma, Allergy and Clinical Immunology. 2005 Guidelines for management of bronchial asthma in Korea. Seoul : Kunja Publications, 2005:3-124
  4. The Korean Academy of Pediatric Allergy and Respiratory Disease. Pediatric allergy, respiratology, and immunology. Seoul : Kunja Publications, 2005:95-130
  5. The Korean Academy of Asthma, Allergy and Clinical Immunology. Allergy in forty millions. Seoul : Euehak-Moonhwa Co, 2005:93-118
  6. National Heart, Lung and Blood Institute/World Health Organization Workshop Report. Global strategy for asthma management and prevention. Bethesda(MD) : NIH; 2002. NIH Publication No. 02-3659
  7. Global Strategy for Asthma Management and Prevention NIH Publication No 02-3659 Issued January, 1995 (updated 2002) Management Segment(Chapter 7) : Updated 2005 from the 2004 document
  8. van Noord JA, Schreurs AJ, Mol SJ, Mulder PG. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999;54:207-12 https://doi.org/10.1136/thx.54.3.207
  9. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Sorkness CA, et al. Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. Long-acting ${\beta}_2$-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma. JAMA 2001;285:2583-93 https://doi.org/10.1001/jama.285.20.2583
  10. Lemanske RF, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, et al. Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol. JAMA 2001; 285:2594-603 https://doi.org/10.1001/jama.285.20.2594
  11. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma : a randomized double-blind placebo-controlled trial. Lancet 2001;357:2007-11 https://doi.org/10.1016/S0140-6736(00)05113-8
  12. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma : systemic review of current evidence. BMJ 2002;324:1-7 https://doi.org/10.1136/bmj.324.7328.1
  13. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than lowdose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000;106:1088-95 https://doi.org/10.1067/mai.2000.110920
  14. Lee HR. A case of fatal asthma in a 31-month old girl. Pediatr Allergy Respir Dis(Korea) 1992;2:34-9